Myeloproliferative disorders in portal vein thrombosis in adults

Tasmin A. Knox, Marshal M. Kaplan – 1 September 1989 – In a prospective study of 33 adults with portal vein thrombosis unrelated to a liver tumor, we have assessed the prevalence of primary myeloproliferative disorders using conventional criteria and cultures of bone marrow progenitor cells. A primary myeloproliferative disorder was documented in 14 patients investigated at the time of recognition of portal vein thrombosis.

Adoptive immunotherapy with lymphokine‐activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

Saburo Onishi, Toshiji Saibara, Masanao Fujikawa, Hiroshi Sakaeda, Yasushi Matsuura, Yoichi Matsunaga, Yasutake Yamamoto – 1 September 1989 – Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokine‐activated killer cells plus recombinant interleukin 2.

A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy

Giorgio Saracco, Giuseppe Mazzella, Floriano Rosina, Claudio Cancellieri, Valter Lattore, Enzo Raise, Giuseppe Rocca, Laura Giorda, Giorgio Verme, Giovanni Gasbarrini, Luigi Barbara, Ferruccio Bonino, Mario Rizzetto, Enrico Roda – 1 September 1989 – Sixty‐four heterosexual Italian carriers of HBsAg with chronic HBeAg and hepatitis B virus DNA‐positive hepatitis were assigned randomly either to receive human lymphoblastoid interferon (injections of 5 million units per m2 three times per week for 6 months) or to serve as untreated controls.

Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: Comparison with immune globulin without vaccine in historical controls

Takehiro Mitsui, Keiko Iwano, Shigeru Suzuki, Chikao Yamazaki, Kazuo Masuko, Fumio Tsuda, Shinobu Aihara, Yoshihiro Akahane, Yuzo Miyakawa, Makoto Mayumi – 1 September 1989 – Twenty‐three staff members serving in a hemodi‐alysis unit were exposed accidentally to needlestick contaminated with blood containing hepatitis B surface antigen and hepatitis B e antigen, as well as high levels of DNA polymerase activity (< 100 cpm).

Detection of antibodies against hepatitis B virus polymerase antigen in hepatitis B virus‐infected patients

Lung‐Ji Chang, Jules Dienstag, Don Ganem, Harold Varmus – 1 September 1989 – By the use of a truncated recombinant hepatitis B virus polymerase antigen, we have characterized a series of patient sera for anti‐hepatitis B virus polymerase antibodies. Seven of 54 (13%) had antipolymerase antibodies detectable by Western blot analysis, and no close correlation was apparent between the disease status and patient's immune response against hepatitis B virus polymerase antigen.

Lack of effects of isosorbide‐5‐mononitrate on hepatic hemodynamics in HBsAg‐positive cirrhosis

Yang‐Te Tsai, Fa‐Yauh Lee, Han‐Chieh Lin, Ting‐Tsung Chang, Chii‐Shyan Lay, Sun‐Sang Wang, Chi‐Woon Kong, Shou‐Dong Lee, Kwang‐Juei Lo – 1 September 1989 – We conducted a randomized controlled hemodynamic study to evaluate the effect of placebo and 20 mg isosorbide‐5‐mononitrate, a long‐acting organic nitrate, in 19 patients with HBsAg‐positive cirrhosis by the simultaneous measurement of portal venous pressure and wedged hepatic venous pressure. Baseline values for the two groups were similar.

Subscribe to